Elecoglipron got 89.6% of participants to the standard glucose target

Elecoglipron, an experimental tablet that works through the GLP-1 receptor, reduced blood sugar significantly more than placebo over 26 weeks. 89.6% of the people who received it reached a hemoglobin A1c of 7 percent, the standard target for many adults with type 2 diabetes, against 24.9% on placebo, and 72.3% lost at least 5 percent of their starting weight against 20.2%.

Swallowing it is the point. Most of this family is injected, and another oral option already available has to be taken on an empty stomach with a wait before food or drink, the sort of rule that makes people abandon a daily medicine. SOLSTICE randomized 406 adults with type 2 diabetes across nine countries against placebo, through a starting phase, a dose-adjustment period and a maintenance stretch, under Vanita Aroda at Mass General Brigham.

Scale is the honest limit. 406 people over 26 weeks is a first look, the comparison was against placebo rather than against the injections this would replace, and hemoglobin A1c is a lab target rather than an outcome measured years later. Tolerability resembled that of the GLP-1 medicines already in clinical use, and the molecule is still in development. Which treatment fits which person is a question for a qualified clinician who knows that person's health history.

Read the full story at Milenio ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.